Skip to main content

Sources last read

FDA report analysis · eight GLP-1 brands

Does a GLP-1 cause gastroparesis?

These drugs slow stomach emptying. The FDA term impaired gastric emptying makes up 5.2% of reports about Ozempic. It appears above the reporting cut-off for only 2 of 8 brands, and both contain semaglutide.

Source for this answer

Source: FDA side-effect reports, read 2026-08-17

Source: FDA side-effect reports, read 2026-08-17

Ozempic and Rybelsus carry a measured share. Every other brand sits below its own cut-off. That is a weaker statement than zero, and it is all the snapshot can support.

Publicity and time on the market can affect reporting. This snapshot does not measure how much those factors contributed, so it cannot use them to explain away a possible drug effect.

Across FDA reports

Products in the table

8

Carrying the term

2

Known only as a ceiling

6

Highest — Ozempic

5.2%

Which products have FDA reports for impaired gastric emptying

One FDA term across eight brands. Two rows contain measured shares; the others only show that the term fell below each product’s cut-off.

◆ impaired gastric emptying — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
impaired gastric emptying — share of each product’s own reports
ProductShare of that product’s reports
Ozempicsemaglutide5.2% of Ozempic reports
Rybelsussemaglutide4.2% of Rybelsus reports
Trulicitydulaglutidebelow 2.1% of Trulicity reports
Wegovysemaglutidebelow 2.0% of Wegovy reports
Saxendaliraglutidebelow 1.9% of Saxenda reports
Zepboundtirzepatidebelow 1.9% of Zepbound reports
Mounjarotirzepatidebelow 1.7% of Mounjaro reports
Victozaliraglutidebelow 1.7% of Victoza reports

Hatched, open-ended bars are ceilings rather than measurements. Read from FDA on 2026-08-17.

A dashed row is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All this page can prove is that it sits at or below the 25th, and that is what the row says.

Every share above is a share of that product’s own reports. It is never a share of the people who took it, because nobody knows how many that is. Two products can differ here for reasons that have nothing to do with either drug.

Both measured rows are the same molecule

Ozempic and Rybelsus are the only brands whose stored terms include it, and both are semaglutide. The tirzepatide and liraglutide products all sit below their own ceilings.

Wegovy is the row that stops this being a clean molecule story. It is semaglutide too, and its share is below its cut-off. So the pattern is not simply semaglutide against everything else.

Products can differ in who uses them and how long they have been on the market. Those differences matter when reading reports, but the saved totals do not show how much they explain.

Another event in the same reports

Vomiting is included as a check because it appears on every label and in FDA reports for most brands. It helps show whether differences are specific to one term or affect the data more broadly.

◆ vomiting — share of each product’s own reportsShare of that product’s reports
8Exact values — 8 rows in the data table
vomiting — share of each product’s own reports
ProductShare of that product’s reports
Rybelsussemaglutide10.0% of Rybelsus reports
Ozempicsemaglutide9.6% of Ozempic reports
Wegovysemaglutide8.7% of Wegovy reports
Saxendaliraglutide7.9% of Saxenda reports
Victozaliraglutide6.9% of Victoza reports
Trulicitydulaglutide6.6% of Trulicity reports
Mounjarotirzepatide5.4% of Mounjaro reports
Zepboundtirzepatide5.0% of Zepbound reports

The same eight products, the same snapshot, a different term. Read from FDA on 2026-08-17.

Can publicity explain the pattern?

Publicity about an event can affect whether it is reported. This data does not isolate reports prompted by news or legal advertising, so it cannot measure their effect on the totals.

A difference between brands may reflect drug effects, patient differences, reporting patterns or a mix of factors. This summary does not establish which explanation accounts for the measured rows.

The reports cannot separate a drug effect from reporting driven by lawsuits. Both the number and that important limitation have to be considered together.

What the labels say about it

The labels describe delayed stomach emptying as part of how the drug acts, not as a surprise. Several also carry warnings about food left in the stomach before a procedure with anesthesia.

So the mechanism is not in question and never was. The open question is whether it turns into a lasting condition in some people. A count of reports is not the study that answers it.

This section summarizes reports people filed. The label guides show what the FDA-approved prescribing information lists. The two answer different questions: what was reported after use, and what was observed in studies.

What this page does and does not establish

A report of slow stomach emptying does not establish a diagnosis of gastroparesis or its cause.

What each claim is supported by in the report data
The claimWhat the evidence shows
These drugs slow stomach emptyingEstablished, and not by this page. It is on the labels, and it is part of how the class works.
Two semaglutide brands carry the term among their most-reportedEstablished for those two. Every other row is a ceiling, which is not the same as a zero.
Semaglutide causes gastroparesis more than tirzepatide doesNot established. Patient differences and reporting patterns may affect the totals. This snapshot cannot separate them from drug effects.
A report here is a diagnosisNot established. FDA does not require a reporter to confirm a diagnosis or to show the drug caused it.

Common questions

Is stomach paralysis the same as gastroparesis?

Stomach paralysis is common wording in news coverage and legal advertising. The clinical term is gastroparesis; FDA reports use impaired gastric emptying.

They are not interchangeable. A slowed stomach is expected on these drugs; a diagnosis of gastroparesis is a separate finding a clinician makes.

Does it go away after stopping?

This snapshot cannot say. It records that a report was filed, with no follow-up and no outcome, so anything about recovery would be invented here.

Why is Wegovy not in the top two?

Its term falls outside Wegovy’s stored top 25. The exact share is unknown, so the snapshot cannot rank it against other bounded rows. Fewer total reports alone would not explain a term’s rank within a product.

Where to go next

This page is one question asked of one snapshot. The pages below answer the neighboring ones from the labels and the trials, which is a different kind of evidence.

Every question in this section is listed on the report-stream questions index.

Read this before quoting anything above

These are counts of reports filed with the FDA, not rates among people treated. This data does not count everyone who used the drug, and a report does not establish that the drug caused the event.

  • No count of everyone treated. FAERS counts submitted reports, not everyone who used a drug. Each percentage here divides an event count by the drug’s report total. It describes a share of reports, not a share of people treated or their chance of an event.
  • A report is not proof the drug did it. FDA does not require proof that a drug caused an event before accepting a report. The drug, an illness or another factor may be involved. A report naming both a drug and an event does not establish the cause.
  • A bigger number can just mean a more-prescribed drug. More reports can simply mean that more people use the drug, that it is newer, or that it receives more news and legal attention. Raw report totals do not tell you which drug is safer.
  • The same event can be counted twice. One event can reach FAERS through more than one channel — the patient, the prescriber and the manufacturer can all file. FDA does not guarantee that the public files are de-duplicated.
  • FDA’s own words. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
  • Retrieved 2026-08-17 from https://api.fda.gov/drug/event.json · FDA data last updated 2026-07-30 · license https://open.fda.gov/license/

How everything on this site is sourced →

10primary sources, each with the day we read it — open the documents used on this page